Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.


Journal article


J Virol

Publication Date





797 - 800


ADP-ribosyl Cyclase, ADP-ribosyl Cyclase 1, Acquired Immunodeficiency Syndrome, Anti-HIV Agents, Antigens, CD, Antigens, Differentiation, Drug Therapy, Combination, HIV-1, Humans, Membrane Glycoproteins, NAD+ Nucleosidase, T-Lymphocytes, Cytotoxic